However, Tα1 has been only administered to the solid organ transplant recipients for the treatment of serious complications such as cytomegalovirus infection and acute respiratory distress syndrome due to pneumonia (39, 40), showing a survival improvement without graft rejection. The gene discussed is TAAR1; the disease is pneumonia.